Clinical Trials
8 trialsNCT00387530 2019-08-02
Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer
University of California, San Diego
Phase 2 Withdrawn
NCT00005639 2019-01-11
Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT00006239 2017-09-29
Phenylbutyrate and Tretinoin in Treating Patients With Hematologic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT00006240 2015-04-28
Phenylbutyrate, Dexamethasone, and Sargramostim in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00006019 2013-06-24
Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00002909 2013-02-05
Phenylbutyrate in Treating Patients With Refractory Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00002796 2013-02-01
Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced Colorectal Cancer
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT00004871 2010-03-10
Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed